Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $796 from $769 and keeps an Equal Weight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $921 from $925 at Bernstein
- Regeneron price target raised to $779 from $765 at RBC Capital
- Regeneron to invest up to $200M in TriNetX as part of strategic collaboration
- Regeneron announces FDA approval of extension of dosing intervals for EYLEA HD
- Regeneron’s High-Dose Aflibercept Trial in China Nears a Key Inflection Point for Eye-Care Growth